<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nierengarten, Mary Beth</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Rutgers, Emiel J. T.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Final Results of AMAROS Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">For breast cancer patients with a positive sentinel node biopsy, treatment with axillary radiotherapy provides excellent locoregional control that is comparable to axillary lymph node dissection but with significantly less lymphedema. This is the conclusion of the final analysis of the Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer trial [AMAROS; NCT00014612; Rutgers EJ et al. J Clin Oncol 2013 (suppl; abstr LBA1001)].</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>